Identity on this record
Composition: Retatrutide 12.5 mg + cagrilintide 2.5 mg.
CAS number: Not applicable — composite material.
Appearance: White to off-white lyophilised blend.
Catalog strength: 15 mg total fill.
Those identifiers describe RETA/CAG as a substance. They do not describe a particular vial. The vial is identified by the name, the nominal fill, and the lot number on its label, checked against the published certificate.
What the catalogue actually sells
Retatrutide + Cagrilintide 15mg (RETA/CAG) is the 15 mg blend lyophilized unit, listed at AED 649 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light.
Prices are merchandise prices in AED, exclusive of VAT. VAT is added at checkout. A price on this summary is the figure on the product record for RETA/CAG, not a delivered-cost quote.
Lots and certificates
Lot VL-RETACAG-20260801 is the catalogue certificate for Retatrutide + Cagrilintide 15mg (RETA/CAG). Read it on Retatrutide + Cagrilintide 15mg (RETA/CAG) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.
How the compound record describes the literature
Retatrutide and cagrilintide appear separately in metabolic research literature; combination presentations require component-level documentation rather than a single-substance CAS identity.
Topics named on the RETA/CAG record, as literature context rather than as outcomes VaultLabs claims: Multi-component incretin / amylin-pathway documentation; Blend identity and ratio analytics; Comparative single-vs-blend handling workflows.
That is context for identifying RETA/CAG. It is not a claim that a vial produces a result in a person, an animal, or a study VaultLabs has not published. VaultLabs does not provide dosage, administration, study-design, or medical guidance.
Points the monograph already states
Points already written on the RETA/CAG monograph, so a reader can check them against that page:
Two named components: retatrutide (12.5 mg) and cagrilintide (2.5 mg) in a 15 mg total fill.
No single CAS registry number — publishing one would misrepresent the blend.
Independent lots from GLP-3 RT 10mg and 20mg single-sequence SKUs.
Cagrilintide appears in amylin-pathway metabolic research literature as a separate substance.
Not for human or veterinary use.
Dispatch and the research-use boundary
VaultLabs dispatches RETA/CAG from Dubai. Orders leave fulfillment within 24 hours, 7 days a week. Standard delivery is AED 35 to every emirate, and delivery is free when the post-discount merchandise subtotal is AED 500 or more. Checkout shows the fee for the address entered. All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use. VaultLabs does not provide dosage, administration, study-design, or medical guidance.
The full narrative record is the RETA/CAG compound monograph. Handling of the sealed unit is the RETA/CAG storage guide. Questions are collected on the RETA/CAG FAQ. How it differs from neighbouring records is the RETA/CAG comparison.